Core Insights - The company, Boan Biotech, has received approval from the National Medical Products Administration of China for its self-developed product, Bo Youjing (Aflibercept intravitreal injection solution), marking the second new product approved this year [1] - Bo Youjing is a biosimilar to EYLEA, targeting various retinal diseases and demonstrating long-term efficacy and good safety profile [1] - The CEO of Boan Biotech highlighted the significant clinical value of Aflibercept and the growing demand for treatment of retinal diseases [2] Product Development - Boan Biotech has successfully launched five products in the past five years, all of which are biosimilars [2] - The company’s first product, Bo Youping, was approved in August as the first domestic Dula-glutide [1][2] Commercialization Strategy - Boan Biotech has partnered with Eucan Vision for commercialization, leveraging a team of hundreds in the ophthalmology field and a network covering over 20,000 hospitals nationwide [1] - The company has also granted exclusive sales rights for Bo Youjing to a subsidiary of Sinovac Biotech in specific regions [1] Financial Performance - For 2024, Boan Biotech projects revenue of 730 million yuan, a year-on-year increase of 17.5%, and a net profit of 73.19 million yuan, marking a turnaround with a profit increase of 190 million yuan [2] - The successful commercialization of new products like Bo Youping and Bo Youjing is expected to enhance the company's profitability and commercial capabilities [2]
博安生物眼科用药博优景获批上市